No records
|
650 |
Jufri M., Vardhani A., Purwaningsih E. |
55542805100;57372533300;57186723500; |
Evaluating the efficacy of lotion containing black rice bran (Oryza sativa L. indica) extract as skin brightening agent: A clinical trial |
2021 |
Jundishapur Journal of Natural Pharmaceutical Products |
16 |
4 |
e114152 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85121121214&doi=10.5812%2fjjnpp.114152&partnerID=40&md5=7475812ecd399617effa3198e4bc8700 |
Faculty of Pharmacy, Universitas Indonesia, Indonesia; Department of Pharmacy, Faculty of Medicine, Universitas Indonesia, Indonesia |
Jufri, M., Faculty of Pharmacy, Universitas Indonesia, Indonesia; Vardhani, A., Faculty of Pharmacy, Universitas Indonesia, Indonesia; Purwaningsih, E., Department of Pharmacy, Faculty of Medicine, Universitas Indonesia, Indonesia |
Background: Ultraviolet exposure is an extrinsic factor to initiate melanogenesis, the process of melanin formation in the skin. Nowadays, natural ingredients tend to be more prevalent in cosmetic formulations due to consumers’ concern about synthetic ingredients and the risks they may represent for human health. Rice bran, the outer layer of a rice grain, can be utilized as a skin-lightening agent. Objectives: This study aimed to determine the efficacy of a lotion containing black rice bran (Oryza sativa L. indica) ethanolic extract as a skin lightening agent. Methods: The black rice bran ethanolic extract was formulated into oil in water (o/w) lotion. In this study, 34 women applied the lotion at one side of the forearm and base placebo lotion as control at the other side of forearm. The results were tested with a paired t-test by GraphPad Prism 8.3.0 software. Results: There was a significant decrease in the melanin index and erythema index in the forearm with a lotion containing black rice bran extract (P-value < 0.0001). Conclusions: The lotion containing 10% black rice bran extract was effective as a skin lightener because it effectively reduced skin melanin production when applied topically. Copyright © 2021, Author(s). |
Black Rice Bran; Clinical Trials; Natural Product; Oryza sativa L. indica; Skin Lightening Agent |
|
Kowsar Medical Institute |
17357780 |
|
|
Article |
Q3 |
228 |
17746 |
|
|
655 |
Ota N., Yoshimoto Y., Darwis N.D.M., Sato H., Ando K., Oike T., Ohno T. |
57359393800;36453407100;57200045716;55697961900;55641963900;36453136000;35395665700; |
High tumor mutational burden predicts worse prognosis for cervical cancer treated with radiotherapy |
2021 |
Japanese Journal of Radiology |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120410945&doi=10.1007%2fs11604-021-01230-5&partnerID=40&md5=4f3db9b90e6b959382e2d0ca7b994c0b |
Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan; Department of Radiation Oncology, School of Medicine, Fukushima Medical University, 1, Hikarigaoka, Fukushima, 960-1295, Japan; Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jl. Diponegoro No. 71, Jakarta Pusat, DKI Jakarta 10430, Indonesia; Gunma University Heavy Ion Medical Center, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan |
Ota, N., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan; Yoshimoto, Y., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan, Department of Radiation Oncology, School of Medicine, Fukushima Medical University, 1, Hikarigaoka, Fukushima, 960-1295, Japan; Darwis, N.D.M., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan, Department of Radiation Oncology, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National General Hospital, Jl. Diponegoro No. 71, Jakarta Pusat, DKI Jakarta 10430, Indonesia; Sato, H., Gunma University Heavy Ion Medical Center, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan; Ando, K., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan; Oike, T., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan, Gunma University Heavy Ion Medical Center, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan; Ohno, T., Department of Radiation Oncology, Gunma University Graduate School of Medicine, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan, Gunma University Heavy Ion Medical Center, 3-39-22, Showa-machi, Maebashi, Gunma 371-8511, Japan |
Purpose: Tumor mutational burden (TMB) is a surrogate biomarker of neo-antigens and high TMB status is associated with favorable response to immune-checkpoint inhibitors (ICIs). This study aimed to elucidate the association between TMB and the outcome of definitive radiotherapy in patients with cervical cancer. Materials and methods: TMB and treatment outcome were retrospectively analyzed in patients with newly diagnosed cervical cancer treated with definitive radiotherapy available with somatic mutation data of pre-treatment tumors obtained using a commercially available gene panel. Results: The study enrolled 98 patients (median follow-up period, 61 months). The median TMB was 9.5 mutations per megabase (range, 3.0–35.5 mutations per megabase). After dichotomization based on this median value, the 5-year overall survival (OS) for TMB-high patients was significantly worse than that of TMB-low patients (61.1% vs. 82.2%). Multivariate analysis identified high TMB status as a significant prognostic factor for worse OS, along with advanced stage, para-aortic lymph node involvement, and absence of concurrent chemotherapy. Conclusion: These data indicate that TMB is a potential prognostic factor for worse survival in patients with cervical cancer treated with definitive radiotherapy, thereby providing a rationale for treatment of TMB-high cervical cancers with a combination of ICIs plus radiotherapy. Secondary abstract: This retrospective study of 98 patients demonstrates for the first time that tumor mutational burden (TMB) is an independent prognostic factor for worse overall survival of patients treated with definitive radiotherapy, providing a rationale for treatment of TMB-high cervical cancers with a combination of immune-checkpoint inhibitors plus radiotherapy. © 2021, The Author(s). |
Cervical cancer; Prognosis; Radiotherapy; Tumor mutational burden |
|
Springer Japan |
18671071 |
|
|
Article |
Q2 |
616 |
8208 |
|
|
656 |
Marwali E.M., Lopolisa A., Sani A.A., Rayhan M., Roebiono P.S., Fakhri D., Haas N.A., Slee A., Portman M.A. |
36608535400;57358496100;57209881028;57219904946;57192895321;8599513100;7103216848;7004895873;7004985824; |
Indonesian Study: Triiodothyronine for Infants Less than 5 Months Undergoing Cardiopulmonary Bypass |
2021 |
Pediatric Cardiology |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120384775&doi=10.1007%2fs00246-021-02779-8&partnerID=40&md5=ee32a32dc863edb4c293caf61a4c9fea |
Pediatric Cardiac Intensive Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Pediatric Cardiology Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Pediatric Cardiac Surgery Unit, National Cardiovascular Center Harapan Kita, Department of Cardiothoracic Vascular Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Pediatric Cardiology and Pediatric Intensive Care, Medical Hospital of the University of Munich, Munich, Germany; Axio Research, Seattle Children’s Hospital and Research Institute, Seattle, United States; Seattle Children’s Hospital, University of Washington, Seattle, WA, United States; National Cardiovascular Center Harapan Kita, Jl. Let. Jend. S. Parman, Kav 87, Slipi, West Jakarta 11420, Indonesia |
Marwali, E.M., Pediatric Cardiac Intensive Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, National Cardiovascular Center Harapan Kita, Jl. Let. Jend. S. Parman, Kav 87, Slipi, West Jakarta 11420, Indonesia; Lopolisa, A., Pediatric Cardiac Intensive Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Sani, A.A., Pediatric Cardiac Intensive Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Rayhan, M., Pediatric Cardiac Intensive Care Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Roebiono, P.S., Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Pediatric Cardiology Unit, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Fakhri, D., Pediatric Cardiac Surgery Unit, National Cardiovascular Center Harapan Kita, Department of Cardiothoracic Vascular Surgery, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Haas, N.A., Department of Pediatric Cardiology and Pediatric Intensive Care, Medical Hospital of the University of Munich, Munich, Germany; Slee, A., Axio Research, Seattle Children’s Hospital and Research Institute, Seattle, United States; Portman, M.A., Seattle Children’s Hospital, University of Washington, Seattle, WA, United States |
This study evaluates the efficacy and safety of oral triiodothyronine on time to extubation for infants less than 5 months undergoing heart surgery in Indonesia, and primarily relates to patients in emerging programs with high malnutrition and mortality. In this randomized, double-blind, placebo-controlled trial, oral triiodothyronine (T3, Tetronine®) 1 μg/kg-body weight/dose or placebo (saccharum lactis) was administered via nasogastric tube every 6 h for 60 h to treatment group. A total of 120 patients were randomized into T3 (61 patients) and placebo (59 patients) groups. The majority of the patients had moderate to severe malnutrition (55.83%) with a high post-operative mortality rate of 23.3%. The T3 group showed significantly higher serum FT3 levels from 1 until 48 h post cross-clamp removal (p < 0.0001), lower incidence of low cardiac output syndrome at both 6 h (28 [45.9%] vs. 39 [66.1%] patients, p = 0.03, OR 2.3, 95% CI: 1.10–4.81) and 12 h after cross-clamp removal (25 [41.7%] vs. 36 [63.2%], p = 0.02, OR 2.40, 95% CI: 1.14–5.05). Although not statistically significant, the treatment group had shorter median (IQR) intubation time (2.59 [1.25–5.24] vs. 3.77 [1.28–6.64] days, p = 0.16, HR 1.36, 95% CI: 0.88–2.09)] and lower mortality (10 [16.4%] vs. 18 [30.5%], p = 0.07]. Patients with Aristotle score < 10.0 (low risk) receiving T3 had faster extubation than placebo patients (p = 0.021, HR of 1.90, 95% CI: 1.10–3.28) and were significantly less likely to require CPR or experience infection (p = 0.027, OR 8.56, 95% CI:0.99–73.9 and p = 0.022, OR 4.09 95% CI: 1.16–14.4, respectively). Oral T3 supplementation reduced overall incidence of low cardiac output syndrome and significantly reduced the time to extubation in low-risk patients. Therefore, prophylactic oral T3 administration may be beneficial in these patients. Trial Registration: ClinicalTrials.gov NCT02222532. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
Congenital open cardiac surgery; Low cardiac output; Time-to-extubation; Triiodothyronine |
|
Springer |
01720643 |
|
|
Article |
Q2 |
646 |
7791 |
|
|
657 |
Irawan C., Benbella L.G., Rachman A., Mansjoer A. |
28767651600;57357413600;15056701600;24335647800; |
Factors that Influence 2-Year Progression-Free Survival Among Head and Neck Cancer Patients |
2021 |
Journal of Epidemiology and Global Health |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120335157&doi=10.1007%2fs44197-021-00016-2&partnerID=40&md5=eae0237d32c525daedf560529a50ad64 |
Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jl. Diponegoro no. 71, Jakarta, 10430, Indonesia; Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia; Cardiology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia |
Irawan, C., Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jl. Diponegoro no. 71, Jakarta, 10430, Indonesia; Benbella, L.G., Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia; Rachman, A., Hematology and Medical Oncology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jl. Diponegoro no. 71, Jakarta, 10430, Indonesia; Mansjoer, A., Cardiology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo National Central General Hospital (RSCM), Jakarta, Indonesia |
Objectives: The majority of patients with head and neck cancer (HNC) come to the hospital at advanced stages. This research was conducted to determine the mortality, 2-year progression-free survival (PFS) and factors that influenced PFS of HNC patients. Methods: A retrospective cohort study was conducted among locally advanced HNC patients who underwent chemoradiation for the first time at RSCM from January 2015 to December 2017. Data were retrieved through medical records. Laboratory data were taken 2–4 weeks prior and 2–4 weeks after chemoradiation. PFS observation started from the first day of chemoradiation until disease progression or death. PFS data were recorded in two groups: ≤ 2 years and > 2 years. The Chi-square test was used for bivariate analysis with the Fischer-exact test as an alternative. Variables will be further tested using multivariate logistic regression tests. Results: Among 216 subjects, there were 103 (47.69%) patients who did not reach overall survival (OS) > 2 years. There were 108 (50%) patients who had PFS > 2 years. Based on the results of multivariate analysis, it was found that smoking, hemoglobin level ≤ 12 g/dl, ECOG (Eastern Cooperative Oncology Group) 1–2, and negative therapeutic response were associated with poor PFS. Hazard ratio (HR) for 2-year PFS for Brinkman index > 250 was 1.36 (95% CI 0.93–2.00; p = 0.02); HR for Hb ≤ 12 g/dl was 1.65 (95% CI 1.13–2.42; p = 0.01); HR for ECOG 1–2 was 4.05 (95% CI 1.49–11.00; p < 0.01); and HR for negative therapeutic response was 2.37 (95% CI 1.43–3.94; p < 0.01). Conclusion: Mortality of HNC patients within 2 years is 47.69%, with a 2-year PFS reaching 50%. Cigarette smoking, low hemoglobin levels, poor performance status, and negative therapeutic response (non-responders) negatively affect the 2-year PFS. © 2021, The Author(s). |
Factor; Head and neck cancer; Mortality; Progression-free survival |
|
Atlantis Press |
22106006 |
|
|
Article |
Q3 |
665 |
7531 |
|
|
660 |
Ramani S., McKimm J., Forrest K., Hays R., Bishop J., Thampy H., Findyartini A., Nadarajah V.D., Kusurkar R., Wilson K., Filipe H., Kachur E. |
56186462600;26433565200;26635053400;7202509928;8406026800;55349958700;56543777300;14048599600;6603461994;56926010000;36657108400;6603938626; |
Co-creating scholarship through collaborative writing in health professions education: AMEE Guide No. 143 |
2021 |
Medical Teacher |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120044813&doi=10.1080%2f0142159X.2021.1993162&partnerID=40&md5=3773bd230107ba738a15f75175eba901 |
Harvard Medical School, Boston, United States; Manchester Medical School, University of Manchester, Manchester, United Kingdom; Swansea University Medical School, United Kingdom; Bond University, Queensland, Australia; James Cook University College of Medicine and Dentistry, James Cook University, Townsville, Australia; Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; International Medical University, Kuala Lumpur, Malaysia; Amsterdam UMC, Research in Education, Faculty of Medicine, Vrije Universiteit, Amsterdam, Netherlands; Dalhousie University, Halifax, NS, Canada; Hospital Egas Moniz, West Lisbon Hospitals Center (NHS), University of Lisbon, Lisboa, Portugal; Medical Education Development, Global Consulting, New York, NY, United States |
Ramani, S., Harvard Medical School, Boston, United States, Manchester Medical School, University of Manchester, Manchester, United Kingdom; McKimm, J., Swansea University Medical School, United Kingdom; Forrest, K., Bond University, Queensland, Australia; Hays, R., James Cook University College of Medicine and Dentistry, James Cook University, Townsville, Australia; Bishop, J., Bond University, Queensland, Australia; Thampy, H., Manchester Medical School, University of Manchester, Manchester, United Kingdom; Findyartini, A., Department of Medical Education, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Nadarajah, V.D., International Medical University, Kuala Lumpur, Malaysia; Kusurkar, R., Amsterdam UMC, Research in Education, Faculty of Medicine, Vrije Universiteit, Amsterdam, Netherlands; Wilson, K., Dalhousie University, Halifax, NS, Canada; Filipe, H., Hospital Egas Moniz, West Lisbon Hospitals Center (NHS), University of Lisbon, Lisboa, Portugal; Kachur, E., Medical Education Development, Global Consulting, New York, NY, United States |
This AMEE guide provides a robust framework and practical strategies for health professions educators to enhance their writing skills and engage in successful scholarship within a collaborative writing team. Whether scholarly output involves peer-reviewed articles, book chapters, blogs and online posts, online educational resources, collaborative writing requires more than the usual core writing skills, it requires teamwork, leadership and followership, negotiation, and conflict resolution, mentoring and more. Whilst educators can attend workshops or courses to enhance their writing skills, there may be fewer opportunities to join a community of scholars and engage in successful collaborative writing. There is very little guidance on how to find, join, position oneself and contribute to a writing group. Once individuals join a group, further questions arise as to how to contribute, when and whom to ask for help, whether their contribution is significant, and how to move from the periphery to the centre of the group. The most important question of all is how to translate disparate ideas into a shared key message and articulate it clearly. In this guide, we describe the value of working within a collaborative writing group; reflect on principles that anchor the concept of writing as a team and guide team behaviours; suggest explicit strategies to overcome challenges and promote successful writing that contributes to and advances the field; and review challenges to starting, maintaining, and completing writing tasks. We approach writing through three lenses: that of the individual writer, the writing team, and the scholarly product, the ultimate goal being meaningful contributions to the field of Health Professions Education. © 2021 AMEE. |
collaborative/peer-to-peer; Continuing; leadership; mentoring; staff development |
|
Taylor and Francis Ltd. |
0142159X |
|
|
Article |
Q1 |
1355 |
2689 |
|
|
662 |
Ta J.W.C., Chew D.P., Tsui K.L., Tan D., Duplyakov D., Hammoudeh A., Zhang B., Li Y., Xu K., Ong P.J., Firman D., Gamra H., Almahmeed W., Dalal J., Tam L.-W., Steg G., Nguyen Q.N., Ako J., Al Suwaidi J., Chan M., Sobhy M., Shehab A., Buddhari W., Wang Z., Fong A.Y.Y., Karadag B., Kim B.-K., Baber U., Chin C.T., Han Y.L. |
57354736300;7102026332;7101671562;50263435900;6506125408;8088443300;56637270100;55914058500;56510776700;7102312670;54898724100;7004594521;6506558682;7004278395;56585509700;57197860836;39962151600;6701389098;6603728555;23388249600;55345664600;6603838351;57192991797;8875501800;14321654600;56243107600;35189204900;16047315200;57226594604;57211831338; |
2021 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region: Special Populations |
2021 |
European Cardiology Review |
16 |
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119968735&doi=10.15420%2fecr.2021.35&partnerID=40&md5=0f474aea7166811035b920e727476fae |
National Heart Centre, Singapore; Sengkang General Hospital, Singapore; College of Medicine and Public Health, Flinders University, Adelaide, Australia; Pamela Youde Nethersole Eastern Hospital, Hong Kong; Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Samara Regional Cardiology Dispensary, Samara, Russian Federation; Cardiology Department, Istishari Hospital, Amman, Jordan; Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore; Tan Tock Seng Hospital, Singapore; Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Cleveland Clinic Abu Dhabi, United Arab Emirates; Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Kwong Wah Hospital, Hong Kong; Department of Cardiology, Hôpital Bichat, Paris, France; Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; National University Heart Centre, Singapore; Faculty of Medicine, Alexandria University, Egypt; College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Sarawak Heart Centre, Kota Samarahan, Malaysia; Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States |
Ta, J.W.C., National Heart Centre, Singapore, Sengkang General Hospital, Singapore; Chew, D.P., College of Medicine and Public Health, Flinders University, Adelaide, Australia; Tsui, K.L., Pamela Youde Nethersole Eastern Hospital, Hong Kong; Tan, D., Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore; Duplyakov, D., Samara Regional Cardiology Dispensary, Samara, Russian Federation; Hammoudeh, A., Cardiology Department, Istishari Hospital, Amman, Jordan; Zhang, B., Department of Cardiology, First Affiliated Hospital, Dalian Medical University, Dalian, China; Li, Y., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China; Xu, K., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Ong, P.J., Heart Specialist International, Mount Elizabeth Novena Hospital, Singapore, Tan Tock Seng Hospital, Singapore; Firman, D., Harapan Kita National Cardiovascular Center, Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia Harapan Kita, Jakarta, Indonesia; Gamra, H., Cardiology Department, Fattouma Bourguiba University Hospital, University of Monastir, Monastir, Tunisia; Almahmeed, W., Cleveland Clinic Abu Dhabi, United Arab Emirates; Dalal, J., Centre for Cardiac Sciences, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India; Tam, L.-W., Kwong Wah Hospital, Hong Kong; Steg, G., Department of Cardiology, Hôpital Bichat, Paris, France; Nguyen, Q.N., Department of Cardiology, Hanoi Medical University, Hanoi, Viet Nam; Ako, J., Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan; Al Suwaidi, J., Adult Cardiology, Hamad Medical Corporation, Doha, Qatar; Chan, M., National University Heart Centre, Singapore; Sobhy, M., Faculty of Medicine, Alexandria University, Egypt; Shehab, A., College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates; Buddhari, W., King Chulalongkorn Memorial Hospital, Bangkok, Thailand; Wang, Z., Department of Cardiology, General Hospital of Shenyang Military, Shenyang, China; Fong, A.Y.Y., Sarawak Heart Centre, Kota Samarahan, Malaysia; Karadag, B., Istanbul University, Cerrahpasa School of Medicine, Istanbul, Turkey; Kim, B.-K., Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea; Baber, U., University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States; Chin, C.T., National Heart Centre, Singapore; Han, Y.L., Department of Cardiology, General Hospital of Northern Theatre Command, Shenyang, China |
Advanced age, diabetes, and chronic kidney disease not only increase the risk for ischaemic events in chronic coronary syndromes (CCS) but also confer a high bleeding risk during antiplatelet therapy. These special populations may warrant modification of therapy, especially among Asians, who have displayed characteristics that are clinically distinct from Western patients. Previous guidance has been provided regarding the classification of high-risk CCS and the use of newer-generation P2Y12inhibitors (i.e. ticagrelor and prasugrel) after acute coronary syndromes (ACS) in Asia. The authors summarise evidence on the use of these P2Y12inhibitors during the transition from ACS to CCS and among special populations. Specifically, they present recommendations on the roles of standard dual antiplatelet therapy, shortened dual antiplatelet therapy and single antiplatelet therapy among patients with coronary artery disease, who are either transitioning from ACS to CCS; elderly; or with chronic kidney disease, diabetes, multivessel coronary artery disease and bleeding events during therapy. © 2021 Radcliffe Group Ltd. All rights reserved. |
Asia; Comorbidity; Consensus; Dual antiplatelet therapy; Myocardial ischaemia; Platelet aggregation inhibitors |
|
Radcliffe Medical Media |
17583756 |
|
|
Article |
Q2 |
864 |
5422 |
|
|
663 |
Mangunatmadja I., Indra R.M., Widodo D.P., Rafli A. |
57195717216;57222298152;57215087823;57210824944; |
Risk Factors for Drug Resistance in Epileptic Children with Age of Onset above Five Years: A Case-Control Study |
2021 |
Behavioural Neurology |
2021 |
|
9092824 |
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119934233&doi=10.1155%2f2021%2f9092824&partnerID=40&md5=74ddaa54df43f8e9dd4e310b0bf1246c |
Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Child Health, Mohammad Hoesin General Hospital, Universitas Sriwijaya, Medical School, Palembang, Indonesia |
Mangunatmadja, I., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Indra, R.M., Department of Child Health, Mohammad Hoesin General Hospital, Universitas Sriwijaya, Medical School, Palembang, Indonesia; Widodo, D.P., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rafli, A., Department of Child Health, Dr. Cipto Mangunkusumo Tertiary General Hospital, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia |
Background. Children with epilepsy with onset above five years encompass distinct epidemiological and clinical characteristics that may have specific risk factors for resistance to antiseizure medications (ASMs). Studies on this age group are limited. Purpose. To identify risk factors for drug resistance in children with epilepsy with the age of onset above five years. Methods. A case-control study was conducted on children with epilepsy with the age of onset above five years visiting the Pediatric Neurology Clinic of Cipto Mangunkusumo and Mohammad Hoesin Hospital between September 2015 and August 2016. Cases consisted of drug-resistant children while control consisted of drug-responsive children according to 2010 ILAE classification. Risk factors studied include onset, number of seizures, illness duration before treatment, cause, seizure type, status epilepticus, initial and evolution of EEG, brain imaging, and initial treatment response. Results. Thirty-two pairs of children were included in the study. After logistic regression analysis, symptomatic etiology and failure to achieve early response to treatment were found to be associated with drug resistance with adjusted OR of 84.71 (95% CI: 5.18-1359.15) and 72.55 (95% CI: 7.08-743.85), respectively. Conclusion. Poor initial response to ASM and symptomatic etiology are independent risk factors for drug resistance in children with epilepsy with the age of onset above five years. © 2021 Irawan Mangunatmadja et al. |
|
anticonvulsive agent; case control study; child; drug resistance; epilepsy; human; onset age; preschool child; risk factor; Age of Onset; Anticonvulsants; Case-Control Studies; Child; Child, Preschool; Drug Resistance; Epilepsy; Humans; Risk Factors |
Hindawi Limited |
09534180 |
|
34804259 |
Article |
Q2 |
859 |
5468 |
|
|
664 |
Han W.M., Law M.G., Choi J.Y., Ditangco R., Kumarasamy N., Chaiwarith R., Ly P.S., Khusuwan S., Merati T.P., Do C.D., Yunihastuti E., Azwa I., Lee M.-P., Pham T.N., Chan Y.-J., Kiertiburanakul S., Ng O.T., Tanuma J., Pujari S., Zhang F., Gani Y., Mave V., Ross J., Avihingsanon A., Ly P.S., Khol V., Zhang F.J., Zhao H.X., Han N., Lee M.P., Li P.C.K., Kwong T.S., Li T.H., Kumarasamy N., Ezhilarasi C., Pujari S., Joshi K., Gaikwad S., Chitalikar A., Sangle S., Mave V., Marbaniang I., Nimkar S., Merati T.P., Wirawan D.N., Yuliana F., Yunihastuti E., Widhani A., Maria S., Karjadi T.H., Tanuma J., Oka S., Nishijima T., Choi J.Y., Na S., Kim J.M., Gani Y.M., Rudi N.B., Azwa I., Kamarulzaman A., SyedOmar S.F., Ponnampalavanar S., Ditangco R., Pasayan M.K., Mationg M.L., Chan Y.J., Ku W.W., Wu P.C., Ke E., Ng O.T., Lim P.L., Lee L.S., Yap T., Ng O.T., Avihingsanon A., Gatechompol S., Phanuphak P., Phadungphon C., Kiertiburanakul S., Phuphuakrat A., Chumla L., Sanmeema N., Chaiwarith R., Sirisanthana T., Praparattanapan J., Nuket K., Khusuwan S., Payoong P., Kantipong P., Kambua P., Pham T.N., Nguyen K.V., Nguyen D.T.H., Nguyen D.T., Do C.D., Ngo A.V., Nguyen L.T., Sohn A.H., Ross J.L., Petersen B., Law M.G., Jiamsakul A., Rupasinghe D., the TREAT Asia HIV Observational Database of IeDEA Asia-Pacific |
57201984684;55556254800;57316129500;55406840800;7003549856;13806165200;9743902800;56166613100;57203678680;56658396600;57221273925;55553159100;57309539000;57213330022;33667461800;6506539792;57350864400;57211702929;57205894660;23007277900;57188842533;24778446900;57193109926;57196347321;57204852770;57188842644;55503803800;35796801900;57206253688;56143671100;57203375227;57350625400;57351089100;55412491000;55413091200;57213607670;35227451500;55273903300;57188839029;6602877716;57425871800;57189801547;56820043000;8935806500;6601921496;57202976978;8850357600;57202561455;57213345044;57219422563;57208428839;57202558648;57226409961;48761023600;57351205400;7601387767;57188842533;57257789600;55553159100;6603019663;55866927600;36768852500;57258598000;57207954173;36936083900;57258255400;55856943500;56514424400;57257813200;57215769524;57210531225;55992506400;57351089200;57203665233;57200282477;57193906863;7004982661;56015716600;57203677438;8277552900;56515326900;55992497800;57203665049;7004277229;35185428900;57192871045;56166613100;57350625500;6603580797;55285745100;57224761710;56370854300;57190300831;56970337500;55035577700;57208054163;41961438300;7006405275;57193720576;56406054800;57222965808;55285745500;57205313395; |
Weight changes, metabolic syndrome and all-cause mortality among Asian adults living with HIV |
2021 |
HIV Medicine |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119685299&doi=10.1111%2fhiv.13211&partnerID=40&md5=043ac7a37890286dc2e8fb917b3e95bc |
The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS Infectious Diseases Medical Centre, VHSChennai, India; Chiang Mai University – Research Institute for Health Sciences, Chiang Mai, Thailand; National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand; Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia; Bach Mai Hospital, Hanoi, Viet Nam; Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; University Malaya Medical Centre, Kuala Lumpur, Malaysia; Queen Elizabeth Hospital, Hong Kong; National Hospital for Tropical Diseases, Hanoi, Viet Nam; Taipei Veterans General Hospital, Taipei, Taiwan; Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore; National Center for Global Health and Medicine, Tokyo, Japan; Institute of Infectious Diseases, Pune, India; Beijing Ditan Hospital, Capital Medical University, Beijing, China; Hospital Sungai Buloh, Sungai Buloh, Malaysia; BJ Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India; TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand |
Han, W.M., The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand; Law, M.G., The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia; Choi, J.Y., Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea; Ditangco, R., Research Institute for Tropical Medicine, Muntinlupa City, Philippines; Kumarasamy, N., Chennai Antiviral Research and Treatment Clinical Research Site (CART CRS), VHS Infectious Diseases Medical Centre, VHSChennai, India; Chaiwarith, R., Chiang Mai University – Research Institute for Health Sciences, Chiang Mai, Thailand; Ly, P.S., National Center for HIV/AIDS, Dermatology & STDs, Phnom Penh, Cambodia; Khusuwan, S., Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand, ; Merati, T.P., Faculty of Medicine, Udayana University & Sanglah Hospital, Bali, Indonesia; Do, C.D., Bach Mai Hospital, Hanoi, Viet Nam; Yunihastuti, E., Faculty of Medicine Universitas Indonesia - Dr. Cipto Mangunkusumo General Hospital, Jakarta, Indonesia; Azwa, I., University Malaya Medical Centre, Kuala Lumpur, Malaysia, ; Lee, M.-P., Queen Elizabeth Hospital, Hong Kong; Pham, T.N., National Hospital for Tropical Diseases, Hanoi, Viet Nam; Chan, Y.-J., Taipei Veterans General Hospital, Taipei, Taiwan; Kiertiburanakul, S., Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; Ng, O.T., Tan Tock Seng Hospital, National Centre for Infectious Diseases, Singapore; Tanuma, J., National Center for Global Health and Medicine, Tokyo, Japan; Pujari, S., Institute of Infectious Diseases, Pune, India; Zhang, F., Beijing Ditan Hospital, Capital Medical University, Beijing, China; Gani, Y., Hospital Sungai Buloh, Sungai Buloh, Malaysia, ; Mave, V., BJ Government Medical College- Johns Hopkins University Clinical Research Site, Pune, India; Ross, J., TREAT Asia, amfAR - The Foundation for AIDS Research, Bangkok, Thailand; Avihingsanon, A., HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Ly, P.S.; Khol, V.; Zhang, F.J.; Zhao, H.X.; Han, N.; Lee, M.P.; Li, P.C.K.; Kwong, T.S.; Li, T.H.; Kumarasamy, N.; Ezhilarasi, C.; Pujari, S.; Joshi, K.; Gaikwad, S.; Chitalikar, A.; Sangle, S.; Mave, V.; Marbaniang, I.; Nimkar, S.; Merati, T.P.; Wirawan, D.N.; Yuliana, F.; Yunihastuti, E.; Widhani, A.; Maria, S.; Karjadi, T.H.; Tanuma, J.; Oka, S.; Nishijima, T.; Choi, J.Y.; Na, S.; Kim, J.M.; Gani, Y.M., Hospital Sungai Buloh, Sungai Buloh, Malaysia, ; Rudi, N.B.; Azwa, I., University Malaya Medical Centre, Kuala Lumpur, Malaysia, ; Kamarulzaman, A.; SyedOmar, S.F.; Ponnampalavanar, S.; Ditangco, R.; Pasayan, M.K.; Mationg, M.L.; Chan, Y.J.; Ku, W.W.; Wu, P.C.; Ke, E.; Ng, O.T.; Lim, P.L.; Lee, L.S.; Yap, T.; Ng, O.T.; Avihingsanon, A.; Gatechompol, S.; Phanuphak, P.; Phadungphon, C.; Kiertiburanakul, S.; Phuphuakrat, A.; Chumla, L.; Sanmeema, N.; Chaiwarith, R.; Sirisanthana, T.; Praparattanapan, J.; Nuket, K.; Khusuwan, S., Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand, ; Payoong, P.; Kantipong, P.; Kambua, P.; Pham, T.N.; Nguyen, K.V.; Nguyen, D.T.H.; Nguyen, D.T.; Do, C.D.; Ngo, A.V.; Nguyen, L.T.; Sohn, A.H.; Ross, J.L.; Petersen, B.; Law, M.G.; Jiamsakul, A.; Rupasinghe, D.; the TREAT Asia HIV Observational Database of IeDEA Asia-Pacific |
Objectives: We investigated weight changes following antiretroviral therapy (ART) initiation, the development of metabolic syndrome (MetS) and its association with all-cause mortality among Asian adults living with HIV. Methods: Participants enrolled in a regional Asian HIV-infected cohort with weight and height measurements at ART initiation were eligible for inclusion in the analysis. Factors associated with weight changes and incident MetS (according to the International Diabetic Federation (IDF) definition) were analysed using linear mixed models and Cox regression, respectively. Competing-risk regression models were used to investigate the association of MetS with all-cause mortality. Results: Among 4931 people living with HIV (PLWH), 66% were male. At ART initiation, the median age was 34 [interquartile range (IQR) 29–41] years, and the median (IQR) weight and body mass index (BMI) were 55 (48–63) kg and 20.5 (18.4–22.9) kg/m2, respectively. At 1, 2 and 3 years of ART, overall mean (± standard deviation) weight gain was 2.2 (±5.3), 3.0 (±6.2) and 3.7 (±6.5) kg, respectively. Participants with baseline CD4 count ≤ 200 cells/µL [weight difference (diff) = 2.2 kg; 95% confidence interval (CI) 1.9–2.5 kg] and baseline HIV RNA ≥ 100 000 HIV-1 RNA copies/mL (diff = 0.6 kg; 95% CI 0.2–1.0 kg), and those starting with integrase strand transfer inhibitor (INSTI)-based ART (diff = 2.1 kg; 95% CI 0.7–3.5 kg vs. nonnucleoside reverse transcriptase inhibitors) had greater weight gain. After exclusion of those with abnormal baseline levels of MetS components, 295/3503 had incident MetS [1.18 (95% CI 1.05–1.32)/100 person-years (PY)]. The mortality rate was 0.7 (95% CI 0.6–0.8)/100 PY. MetS was not significantly associated with all-cause mortality in the adjusted model (P = 0.236). Conclusions: Weight gain after ART initiation was significantly higher among those initiating ART with lower CD4 count, higher HIV RNA and an INSTI-based regimen after controlling for baseline BMI. Greater efforts to identify and manage MetS among PLWH are needed. © 2021 British HIV Association |
all-cause mortality; Asian people living with HIV; HIV/AIDS; metabolic syndrome; weight gain |
|
John Wiley and Sons Inc |
14642662 |
|
34816562 |
Article |
Q1 |
1530 |
2201 |
|
|
666 |
Sukrisman L., Sinto R. |
8661764000;36099377100; |
Coagulation profile and correlation between D-dimer, inflammatory markers, and COVID-19 severity in an Indonesian national referral hospital |
2021 |
Journal of International Medical Research |
49 |
11 |
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119613636&doi=10.1177%2f03000605211059939&partnerID=40&md5=c946e5b0ffec2b5ef4b8bd521da19dbf |
Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia |
Sukrisman, L., Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia; Sinto, R., Division of Tropical and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National Hospital, Jakarta, Indonesia |
Background: Coagulopathy and inflammation are associated with coronavirus disease 2019 (COVID-19) severity. This study assessed D-dimer concentration and its correlation with inflammatory markers and COVID-19 severity. Methods: This was a retrospective cross-sectional study involving 194 COVID-19 cases, with the severity of infection graded in accordance with the World Health Organization (WHO) guidelines. We measured D-dimer, C-reactive protein (CRP), and ferritin on admission and determined the cutoff values for D-dimer and CRP and evaluated the correlation between D-dimer and CRP and ferritin. Results: Median D-dimer, CRP, and ferritin concentrations were 2240 µg/L, 73.2 mg/L, and 1173.8 µg/mL, respectively. The highest median D-dimer value was seen in mild and moderate acute respiratory distress syndrome (ARDS). The highest ferritin concentration was seen in severe ARDS. There was a significant correlation between D-dimer value and CRP (r = 0.327), but no significant correlation between D-dimer and ferritin (r = 0.101). The area under the receiver operating characteristic curve (AUC) for the combination of CRP ≥72.65 mg/L and D-dimer ≥1250 µg/L as a marker of COVID-19 severity was 0.722 (95% confidence interval (CI): 0.615–0.781). Conclusion: The combination of CRP ≥72.65 mg/L and D-dimer ≥1250 µg/L can be used as marker of COVID-19 severity, with moderate accuracy. © The Author(s) 2021. |
acute respiratory distress syndrome; C-reactive protein; Coronavirus disease 2019; correlation; D-dimer; ferritin; inflammation; severity |
biological marker; fibrin degradation product; fibrin fragment D; cross-sectional study; hospital; human; Indonesia; patient referral; retrospective study; severity of illness index; Biomarkers; COVID-19; Cross-Sectional Studies; Fibrin Fibrinogen Degradation Products; Hospitals; Humans; Indonesia; Referral and Consultation; Retrospective Studies; SARS-CoV-2; Severity of Illness Index |
SAGE Publications Ltd |
03000605 |
|
34796762 |
Article |
Q3 |
421 |
11626 |
|
|
667 |
Lesmana C.R.A., Paramitha M.S., Gani R.A., Lesmana L.A. |
8977683000;57212562901;23495930300;55920139300; |
The role of endoscopic ultrasound for portal hypertension in liver cirrhosis |
2021 |
Journal of Medical Ultrasonics |
|
|
|
|
|
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119500644&doi=10.1007%2fs10396-021-01165-4&partnerID=40&md5=72338502ade4f82a944b72db4fee4c65 |
Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia |
Lesmana, C.R.A., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia, Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia; Paramitha, M.S., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Gani, R.A., Hepatobiliary Division, Department of Internal Medicine, Dr. Cipto Mangunkusumo National General Hospital, Medical Faculty Universitas Indonesia, Jakarta, Indonesia; Lesmana, L.A., Digestive Disease and GI Oncology Center, Medistra Hospital, Jakarta, Indonesia |
Chronic liver disease is still a major problem because disease progression will ultimately lead to liver cirrhosis. Portal hypertension is the hallmark in advanced liver disease management. By establishing portal vein access, endoscopic ultrasound (EUS) has been utilized in various clinical applications. In comparison to standard upper gastrointestinal endoscopy, EUS-Doppler has been shown to be a better modality for detecting esophageal and gastric varices along with peri-esophageal collateral veins, para-esophageal collateral veins, and perforating veins, and may be used to objectively predict the recurrence of bleeding. EUS-guided portal vein catheterization has also been proposed to overcome the limitations of trans-jugular approaches. The combination of EUS-elastography and azygos vein evaluation can also enhance the diagnostic accuracy of each modality. Another well-known implementation of EUS-guided procedures is in the management of ascites; particularly in paracentesis and ascitic fluid analysis. In addition, the most common clinical application of EUS in the treatment of portal hypertension is through vascular therapy or creation of intrahepatic portosystemic shunts. Major drawbacks of EUS mainly revolve around technical difficulties, the high cost of the procedure, as well as the requirement of more studies in humans to evaluate EUS-guided advanced therapeutic modalities in portal hypertension. © 2021, The Author(s), under exclusive licence to The Japan Society of Ultrasonics in Medicine. |
Endoscopic ultrasound; Liver cirrhosis; Portal hypertension |
|
Springer |
13464523 |
|
|
Review |
#N/A |
#N/A |
#N/A |
|
|